Ethnicity and Patient Outcomes in the TOP MS Study

T. Leist,¹ H. Zwibel,² C. Markowitz,³ B. Cohen,⁴ P. K. Coyle,⁵ M. Tullman,⁶ M. Oleen-Burkey,⁷ M. Schwartz⁸

¹Thomas Jefferson University, Philadelphia, PA; ²Neuroscience Consultants, Coral Gables, FL; ³University of Pennsylvania, Philadelphia, PA; ⁴Northwestern University, Chicago, IL; ⁵Stony Brook University, Stony Brook, NY; ⁶Missouri Baptist Medical Center, St. Louis, MO; ⁷Outcomes Scribe, LLC, Leawood, KS; ⁸MedNet Solutions, Minnetonka, MN

INTRODUCTION

- Multiple sclerosis (MS) is recognized in almost all ethnic groups around the world.²
- Worldwide prevalence data imply that racial and ethnic differences are important in influencing the distribution of MS.¹
- Recent studies in the United States, Europe and Brazil have suggested there is faster clinical progression and greater disability in MS patients of African descent.²⁻⁵

OBJECTIVES

• To investigate the characteristics of two ethnic groups, African Americans (AA) and Caucasians (C) and the relationship of therapy adherence to MS relapses and disability, among patients who have completed the Therapy Optimization in MS (TOP MS) study.

METHODS

- Enrollees in TOP MS, a prospective, open-label, observational study had a diagnosis of MS and were prescribed glatiramer acetate (GA) or an interferon β (IFN- β) dispensed by a participating specialty pharmacy.
- Additional Inclusion Criteria for these analyses:
 - Relapsing forms of MS
 - Self-reported EDSS scores at baseline and Month 24 without simultaneous confirmed relapses.
- Exclusion Criteria for TOP MS included:
 - Any condition that might interfere with participation or with assessments for the full duration of the study;
 - Any contraindication to GA or IFN- β therapy, including pregnancy, trying to become pregnant or breast feeding;
 - Receiving any experimental drug in the 30 days prior to enrollment.
- Participants submitted signed informed consents to their respective pharmacies.
- Study enrollment produced log-on instructions for the study website where responses were entered at regular intervals throughout the study.
- Disease-modifying therapy (DMT) shipment dates for study participants were uploaded to the study database by the pharmacies at regular intervals and the adherence measure, medication possession ratio (MPR), was calculated each quarter.
 - MPR is a ratio of days that the subject has drug to take at the prescribed frequency (syringe counts) compared to the number of days in the interval (i.e., 24 months). [Expressed as decimal 0.1 to 1.0 in this presentation.]
- Logistic regression was used to examine the association between physician confirmed relapses, ethnicity and DMT MPR.
 - <u>Relapses</u> were counted for these analyses only if they were <u>confirmed</u> by a physician and/or were treated with corticosteroids.
- Linear regression was used to examine the association of 24-month EDSS, ethnicity and DMT MPR accounting for baseline EDSS.

RESULTS

- C ethnicities.

Table 1. Demographic Characteristics

Characterist

Age (Yrs)

Time since

Duration of

Self-Report

Characterist

Gender (n/9 Employme Full Time Part Time

Unemploy Disabled Other*

MPR 0 to 0.5 >0.5 to ≤0.8

>0.8 to 1.0

• Of the 2,243 eligible TOP MS completers, 127 (5.7%) reported AA and 2,116

 There were no baseline differences between the ethnic groups in the distribution of DMT used (50.8% GA and 49.2% IFN- β), prior use of another DMT (34.6%) or reasons for changing therapies.

At the start of the study, there were more AA patients on disability due to MS and their self-reported EDSS was higher with a shorter duration of disease and a younger age than the C cohort (Table 1).

The AA cohort self-reported missing 40% more DMT doses each month (*p* < 0.001) than the C cohort and this is reflected in the MPR from drug shipments. **Table 2** presents the MPR by ethnic group.

African American Cohort (n = 127)		Caucasian Cohort (2116)	
Mean	SD	Mean	SD
46.2	10.5	50.0	9.8
8.2	7.6	11.9	9.4
3.4	3.5	4.9	4.2
3.7	2.6	2.9	2.5
n	%	n	%
111	87.4	1704	80.5
54	42.5	975	46.1
4	3.1	216	10.2
8	6.3	75	3.5
47	37.0	440	20.8
14	11.1	410	19.4
	Coh (n = 1 Mean 46.2 8.2 3.4 3.4 3.7 n 111 54 4 8 4 4	Cohort $(n = 127)$ MeanSD46.210.58.27.63.43.53.72.611187.45442.543.186.34737.0	Cohort $(n = 127)$ Cohor (211) MeanSDMean46.210.550.08.27.611.93.43.54.93.72.62.9n%n11187.417045442.597543.121686.3754737.0440

All comparisons are statistically significant: Gender p = 0.05; all others: p < 0.0001SD = standard deviation; DMT = Disease-Modifying Therapy


*Other (Employed at Home 2 vs. 49; Homemaker 1 vs. 149; Student 2 vs. 12; Workers Comp. 0 vs. 1; and Retired 9 vs. 199).


Table 2. Percentage of Each Ethnic Group by MPR Category When Remaining on the Same Therapy*

African American Cohort (n = 106) %	Caucasian Cohort (n = 1806) %	Total (n = 1912) %		
8.5	5.2	5.4		
43.4	30.8	31.5		
48.1	64.0	63.1		
these remaining on the same therapy for 24 menths				

*Includes only those remaining on the same therapy for 24 months MPR = Medication Possession Ratio

- change from baseline in EDSS (Figure 2).
- **Regression Results:**





There were no significant differences between the ethnic cohorts on study in the number of physician-confirmed relapses, proportion relapse-free (Figure 1) or

- Odds of relapse for a patient in the MPR >0.9 group was 0.6073 or 61% of that of a patient in the MPR < 0.5 category (p = 0.038) regardless of ethnicity.

- Ethnicity and levels of MPR were not significantly related to 24-month EDSS changes.

CONCLUSIONS

- The AA vs. C group in the TOP MS Study showed a more severe disease profile at entry and reported poorer DMT adherence during the twoyear study.
- Although mean relapse and EDSS change on study did not differ, relapse rate was significantly less in patients with DMT adherence greater than 90% regardless of ethnicity.

REFERENCES

- 1. Rosati G. Neurol Sci 2001;22:117-39.
- 2. Weinstock-Guttman B, Jacobs LD, Brownscheidle CM, et al. *Multi Scler* 2003;9:293-98.
- 3. Kaufman MD, Johnson SK, Moyer D, Bivens J, Norton HJ. Am J Phys Med Rehabil 2003; 82:582-90
- 4. Ferreira Vasconcelos CC, Cruz Dos Santos GA, Thuler LC, et al. *ISRN Neurol* 2012; Epub 2012 Nov 25. doi: 10.5402/2012/410629.
- 5. Langer-Gould A, Brara SM, Beaber BE, Zhang JL. Neurology 2013;80:1734-9.

ACKNOWLEDGMENTS

The authors wish to acknowledge the contributions of MedNet Solutions and the Study Managers at the Specialty Pharmacies: Cora Edwards, CCRP, Diplomat Specialty Pharmacy; Kira Botkin, BioScrip Inc.; and Christina Makowski and Dann Yelen, Walgreens, as well as Iris Culbert, MSHS, who has managed the TOP MS Study for Teva Branded Pharmaceutical Products R&D. The study was funded by Teva Branded Pharmaceutical, Products R&D, Inc., Kansas City, MO, USA.

DISCLOSURES

T. Leist received personal compensation for consulting from Bayer, Biogen IDEC, EMD Serono, Sanofi Aventis, and Teva Neuroscience. Dr. Leist also received financial support for research activities from Bayer, EMD Serono and Teva Neuroscience. H. Zwibel is or has been a consultant to Acorda Therapeutics, Bayer, Biogen, EMD Serono, Genentech, and Teva Neuroscience, a member of the speakers bureau for Acorda Therapeutics, Biogen, EMD Serono and Teva Neuroscience, and is a member of the advisory board for WebMD, LLC (Medscape). **C. Markowitz** received personal compensation for consulting from Bayer, Biogen Idec, Eli Lilly, EMD-Serono, and Teva Neuroscience. B. Cohen received consulting compensation from Acorda, Astellas, Biogen-Idec, EMD-Serono, Genzyme, Sanofi-Aventis, and Teva Neuroscience. Dr. Cohen also received research support through Northwestern University from NIH, Biogen-Idec, EMD Serono, Novartis, and Hoffman La Roche and funding support through Northwestern University for a CME course from Teva Neuroscience. **P. K. Coyle** received personal compensation for consulting and development of educational material from Accordant, Acorda, Bayer, Biogen Idec, EMD Serono, Genzyme/Sanofi Aventis, Novartis, Roche, and Teva. Dr. Coyle also received research support from clinical trials sponsored by Actelion, Avanir, Novartis and Opexa. M. **Tullman** received consulting/lecture fees from Allergan, Acorda Therapeutics, Biogen Idec, EMD Serono, Genzyme, Novartis, Pfizer, and Teva Neuroscience. M. Oleen-Burkey received consulting compensation from Teva Branded Pharmaceutical Products R&D, Inc. M. Schwartz is an employee of MedNet Solutions and receives compensation as a statistical consultant to Teva Branded Pharmaceutical Products R&D, Inc, for this study.

Presented at the 2013 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and the Fifth Cooperative Meeting with Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Orlando, Florida, USA, May 29 - June 1, 2013